MedGen

A primary tumor TNM finding indicating that there is no evidence of primary tumor. [from NCI]

No evidence of primary tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015) [from NCI]

AIDS-related Kaposi sarcoma is only in the skin and/or the lymph nodes, and/or there is only a small amount of disease on the palate. The Kaposi sarcoma lesions in the mouth are flat rather than raised. (American Cancer Society) [from NCI]

The following combinations of tumor and systemic illness status define good risk AIDS-related Kaposi sarcoma: T0 S0, T1 S0, or T0 S1. T0: Localized tumor. T1: Widespread tumor. S0: No systemic illness is present. S1: Systemic illness is present. (American Cancer Society) [from NCI]

Stage IIIC2 includes: TX, T0, T1-3, N2, M0. TX: Primary tumor cannot be assessed. T0: No evidence of primary tumor. T1: Tumor strictly confined to the cervix (extension to corpus should be disregarded). T2: Tumor invading beyond the uterus but not to the pelvic wall or to lower third of vagina. T3: Tumor extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. Cases with no cancer-free space between the tumor and pelvic wall by rectal examination are FIGO III. N2: Tumor with regional lymph node metastasis to para-aortic lymph nodes with or without positive pelvic lymph nodes. M0: No distant metastasis. (from AJCC 9th Ed.) [from NCI]

Stage II includes: (T1, N1, M0); (T0, N1, M0); (T2, N0, M0); (T2, N1, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage III includes: (T1, N2, M0); (T0, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). T3: Tumor infiltrating bony structures at skull base, cervical vertebrae, pterygoid structures, and/or paranasal sinuses. N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.) [from NCI]

Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+). (AJCC 7th Ed.) [from NCI]

Stage IIIC includes: IIIC1: TX, T0, T1-3, N1, M0; IIIC2: TX, T0, T1-3, N2, M0. TX: Primary tumor cannot be assessed. T0: No evidence of primary tumor. T1: Tumor strictly confined to the cervix (extension to corpus should be disregarded). T2: Tumor invading beyond the uterus but not to the pelvic wall or to lower third of vagina. T3: Tumor extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. Cases with no cancer-free space between the tumor and pelvic wall by rectal examination are FIGO III. N1: Tumor with regional lymph node metastasis to pelvic lymph nodes only. N2: Tumor with regional lymph node metastasis to para-aortic lymph nodes with or without positive pelvic lymph nodes. M0: No distant metastasis. (from AJCC 9th Ed.) [from NCI]

Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage IIIC1 includes: TX, T0, T1-3, N1, M0. TX: Primary tumor cannot be assessed. T0: No evidence of primary tumor. T1: Tumor strictly confined to the cervix (extension to corpus should be disregarded). T2: Tumor invading beyond the uterus but not to the pelvic wall or to lower third of vagina. T3: Tumor extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. Cases with no cancer-free space between the tumor and pelvic wall by rectal examination are FIGO III. N1: Tumor with regional lymph node metastasis to pelvic lymph nodes only. M0: No distant metastasis. (from AJCC 9th Ed.) [from NCI]

Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage IIIC includes: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.) [from NCI]

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.) [from NCI]

Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0). T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T0: No evidence of primary tumor. N0: No regional lymph node metastasis. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+). (AJCC 7th Ed.) [from NCI]

Stage II includes: (T0, N2, M0); (T1, N2, M0) ;(T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. N2: Tumor with contralateral or bilateral lymph nodes metastasis, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]

Stage II includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes. N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.) [from NCI]